These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 31809979)
1. Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy. Alayed Y; Davidson M; Quon H; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Liu SK; Panjwani D; Helou J; Musunuru HB; Pang G; Korol R; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Commisso A; Commisso K; D'Alimonte L; Ho L; Bhounr Z; Loblaw A Radiother Oncol; 2020 Mar; 144():135-140. PubMed ID: 31809979 [TBL] [Abstract][Full Text] [Related]
2. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy. Elias E; Helou J; Zhang L; Cheung P; Deabreu A; D'Alimonte L; Sethukavalan P; Mamedov A; Cardoso M; Loblaw A Radiother Oncol; 2014 Jul; 112(1):83-8. PubMed ID: 25005578 [TBL] [Abstract][Full Text] [Related]
3. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270 [TBL] [Abstract][Full Text] [Related]
4. Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer. Ong WL; Davidson M; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A Radiother Oncol; 2023 Nov; 188():109864. PubMed ID: 37619656 [TBL] [Abstract][Full Text] [Related]
5. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study. Büchser D; Casquero F; Espinosa JM; Perez F; Minguez P; Martinez-Indart L; Suarez F; Gonzalez A; Cacicedo J; San Miguel I; Maleta A; Gomez-Caamaño A; Bilbao P; Gomez-Iturriaga A Radiother Oncol; 2019 Jun; 135():13-18. PubMed ID: 31015158 [TBL] [Abstract][Full Text] [Related]
6. Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer. Musunuru HB; Davidson M; Cheung P; Vesprini D; Liu S; Chung H; Chu W; Mamedov A; Ravi A; D'Alimonte L; Commisso K; Helou J; Deabreu A; Zhang L; Loblaw A Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1043-51. PubMed ID: 27026311 [TBL] [Abstract][Full Text] [Related]
7. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166 [TBL] [Abstract][Full Text] [Related]
8. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Alayed Y; Quon H; Ong A; Cheung P; Chu W; Chung H; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A Radiother Oncol; 2020 Aug; 149():8-13. PubMed ID: 32416376 [TBL] [Abstract][Full Text] [Related]
9. An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity. Henderson DR; Murray JR; Gulliford SL; Tree AC; Harrington KJ; Van As NJ Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):539-547. PubMed ID: 29807801 [TBL] [Abstract][Full Text] [Related]
10. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study. Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020 [TBL] [Abstract][Full Text] [Related]
11. Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Repka MC; Carrasquilla M; Paydar I; Wu B; Lei S; Suy S; Collins SP; Kole TP Acta Oncol; 2023 Feb; 62(2):174-179. PubMed ID: 36826994 [TBL] [Abstract][Full Text] [Related]
12. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning. Pan X; Levin-Epstein R; Huang J; Ruan D; King CR; Kishan AU; Steinberg ML; Qi XS Radiother Oncol; 2020 Jul; 148():181-188. PubMed ID: 32388444 [TBL] [Abstract][Full Text] [Related]
13. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials. Alayed Y; Quon H; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Panjwani D; Helou J; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Commisso A; Commisso K; Loblaw A Radiother Oncol; 2019 Nov; 140():105-109. PubMed ID: 31265940 [TBL] [Abstract][Full Text] [Related]
15. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer. Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517 [TBL] [Abstract][Full Text] [Related]
16. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547 [TBL] [Abstract][Full Text] [Related]
17. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy. Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069 [TBL] [Abstract][Full Text] [Related]
18. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807 [TBL] [Abstract][Full Text] [Related]
19. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial. Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080 [TBL] [Abstract][Full Text] [Related]
20. Dose constraints in the rectum and bladder following carbon-ion radiotherapy for uterus carcinoma: a retrospective pooled analysis. Okonogi N; Fukahori M; Wakatsuki M; Ohkubo Y; Kato S; Miyasaka Y; Tsuji H; Nakano T; Kamada T Radiat Oncol; 2018 Jun; 13(1):119. PubMed ID: 29941040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]